Long-Term Efficacy and Safety of Risankizumab for csDMARD-IR Patients With Active Psoriatic Arthritis: 196-Week Results From the KEEPsAKE 1 Trial. (2024). SKIN The Journal of Cutaneous Medicine, 8(6), s445. https://doi.org/10.25251/skin.8.supp.445